Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response

J Gastrointest Cancer. 2019 Dec;50(4):943-946. doi: 10.1007/s12029-018-0130-3.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Administration, Oral
  • Adult
  • Aged, 80 and over
  • Drug Resistance, Neoplasm
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / therapy*
  • Esophagus / pathology
  • Esophagus / surgery
  • Fatal Outcome
  • Female
  • Humans
  • Indazoles
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Pyrimidines / administration & dosage*
  • Stomach / pathology
  • Stomach / surgery
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*
  • Sulfonamides / administration & dosage*
  • Treatment Outcome

Substances

  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • pazopanib